Actively Recruiting

Phase Not Applicable
Age: 18Years +
MALE
NCT06200259

Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement

Led by Covenant Health Cancer Center · Updated on 2025-12-18

500

Participants Needed

1

Research Sites

733 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This purpose of this study is to examine the placement of proton spots during pencil beam scanning proton therapy for low and intermediate risk prostate cancer. The researchers will test a unique technique called "Spot Delete" to control the placement of spots during treatment planning. They will also use a special computer model to study how the energy of the proton beam (linear energy transfer) is related to rectal and bladder side effects. The study involves creating a treatment plan based on a CT scan, which helps guide the proton beam in the body. The clinical team uses this CT scan to find the best placement for the protons. The "Spot Delete" method prevents protons from stopping in the rectum, sigmoid, and small bowel, which is thought to be related to acute or late toxicities, such as tenesmus, diarrhea, fecal incontinence, proctitis, and rectal hemorrhage.

CONDITIONS

Official Title

Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement

Who Can Participate

Age: 18Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Pathologically confirmed diagnosis of prostatic adenocarcinoma
  • Clinical stage T1-T2c based on history and physical exam
  • Prostate specific antigen (PSA) less than 20 ng/mL
  • Gleason Score of 7 or lower
  • Eastern Cooperative Oncology Group (ECOG) Performance status 0-1
  • Male patients 18 years of age or older
  • Willing and able to complete IPSS survey and EPIC questionnaire
Not Eligible

You will not qualify if you...

  • Previous radiotherapy to the pelvic area
  • Prior prostate cancer treatments such as cryotherapy or hyperthermia
  • Prior chemotherapy for prostate cancer
  • Treatment targeting regional lymph nodes (common iliac, external iliac, internal iliac, presacral)
  • Active diverticulitis, ulcerative colitis, or Crohn's disease

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Thompson Proton Center

Knoxville, Tennessee, United States, 37909

Actively Recruiting

Loading map...

Research Team

S

Samantha Hedrick, PhD, DABR

CONTACT

C

Catherine Duke-Taylor, BS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here